Literature DB >> 34299330

Fatty Acid Amide Hydrolase (FAAH) Inhibition Modulates Amyloid-Beta-Induced Microglia Polarization.

Maddalena Grieco1, Maria Giovanna De Caris2, Elisa Maggi3, Federica Armeli3, Roberto Coccurello4,5, Tiziana Bisogno6, Maria D'Erme1, Mauro Maccarrone7,8, Patrizia Mancini2, Rita Businaro3.   

Abstract

The ability of endocannabinoid (eCB) to change functional microglial phenotype can be explored as a possible target for therapeutic intervention. Since the inhibition of fatty acid amide hydrolase (FAAH), the main catabolic enzyme of anandamide (AEA), may provide beneficial effects in mice model of Alzheimer's disease (AD)-like pathology, we aimed at determining whether the FAAH inhibitor URB597 might target microglia polarization and alter the cytoskeleton reorganization induced by the amyloid-β peptide (Aβ). The morphological evaluation showed that Aβ treatment increased the surface area of BV-2 cells, which acquired a flat and polygonal morphology. URB597 treatment partially rescued the control phenotype of BV-2 cells when co-incubated with Aβ. Moreover, URB597 reduced both the increase of Rho protein activation in Aβ-treated BV-2 cells and the Aβ-induced migration of BV-2 cells, while an increase of Cdc42 protein activation was observed in all samples. URB597 also increased the number of BV-2 cells involved in phagocytosis. URB597 treatment induced the polarization of microglial cells towards an anti-inflammatory phenotype, as demonstrated by the decreased expression of iNOS and pro-inflammatory cytokines along with the parallel increase of Arg-1 and anti-inflammatory cytokines. Taken together, these data suggest that FAAH inhibition promotes cytoskeleton reorganization, regulates phagocytosis and cell migration processes, thus driving microglial polarization towards an anti-inflammatory phenotype.

Entities:  

Keywords:  M1/M2 phenotypes; N-arachidonoylethanolamine (AEA); URB597; actin cytoskeleton; cell migration; fatty acid amide hydrolase (FAAH); microglia; neuroinflammation

Year:  2021        PMID: 34299330     DOI: 10.3390/ijms22147711

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  5 in total

Review 1.  Phytocannabinoids and Cannabis-Based Products as Alternative Pharmacotherapy in Neurodegenerative Diseases: From Hypothesis to Clinical Practice.

Authors:  Yolanda Paes-Colli; Andrey F L Aguiar; Alinny Rosendo Isaac; Bruna K Ferreira; Raquel Maria P Campos; Priscila Martins Pinheiro Trindade; Ricardo Augusto de Melo Reis; Luzia S Sampaio
Journal:  Front Cell Neurosci       Date:  2022-05-30       Impact factor: 6.147

2.  Special Issue "Microglia Heterogeneity and Its Relevance for Translational Research".

Authors:  Alessandro Michelucci; Veronique E Miron; Josef Priller
Journal:  Int J Mol Sci       Date:  2021-11-16       Impact factor: 5.923

Review 3.  Microglial Endocannabinoid Signalling in AD.

Authors:  Lucia Scipioni; Francesca Ciaramellano; Veronica Carnicelli; Alessandro Leuti; Anna Rita Lizzi; Noemi De Dominicis; Sergio Oddi; Mauro Maccarrone
Journal:  Cells       Date:  2022-04-06       Impact factor: 6.600

4.  Gene Expression Analysis of the Endocannabinoid System in Presymptomatic APP/PS1 Mice.

Authors:  Laura Vidal-Palencia; Carla Ramon-Duaso; Jose Antonio González-Parra; Arnau Busquets-Garcia
Journal:  Front Pharmacol       Date:  2022-03-18       Impact factor: 5.810

Review 5.  Macrophages: A communication network linking Porphyromonas gingivalis infection and associated systemic diseases.

Authors:  Jie Lin; Dingming Huang; Hongwei Xu; Fenghuang Zhan; XueLian Tan
Journal:  Front Immunol       Date:  2022-07-27       Impact factor: 8.786

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.